Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523570 | 0.99 | TRPV3 (0.36) | TRPV3HPGDMEN1KMT2ACNR2 | |
| SCHEMBL4500319 | 0.87 | HPGD (0.39) | HPGDMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL3138155 | 0.86 | RAB9A (0.38) | HPGDMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL3493488 | 0.84 | CNR1 (0.41) | CNR2RAB9ANPC1CNR1CHRM1 | |
| SCHEMBL3493482 | 0.84 | CNR1 (0.41) | CNR2RAB9ANPC1CNR1CHRM1 | |
| SCHEMBL13600526 | 0.82 | CNR2 (0.33) | CNR2 | |
| SCHEMBL4489665 | 0.81 | HPGD (0.41) | HPGDMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL4487940 | 0.80 | HPGD (0.41) | HPGDMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL3491426 | 0.80 | NPC1 (0.40) | HPGDRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3128705 | 0.80 | GNE (0.40) | HPGDMEN1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298835-A1 | NOVEL SCAFFOLDS FOR ALPHA-HELIX MIMICRY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298835-A1 | NOVEL SCAFFOLDS FOR ALPHA-HELIX MIMICRY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-03 | — | — | US | disclosed |
| US-7579350-B2 | 5-Isobutyl-6-4-isopropyl-4,5-dihydro-oxazol-2-yl)-pyridazin-3-yl]-piperidin-1-yl-methanone; mimetics of functionalized pyridazine derivatives having low molecular weight; alpha-helical binding ligands of natural receptors such as those of the peptide galanin or the protein Bcl | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579350-B2 | 5-Isobutyl-6-4-isopropyl-4,5-dihydro-oxazol-2-yl)-pyridazin-3-yl]-piperidin-1-yl-methanone; mimetics of functionalized pyridazine derivatives having low molecular weight; alpha-helical binding ligands of natural receptors such as those of the peptide galanin or the protein Bcl | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298835-A1 | NOVEL SCAFFOLDS FOR ALPHA-HELIX MIMICRY | HRH1, HEATR1, PLEKHA1 | TRPV3 1926/4885HPGD 2198/4885MEN1 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.